Comparison of BlephEx to MiBoflo as Treatment Options for Blepharitis
| Status: | Completed |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 6/10/2018 |
| Start Date: | May 2015 |
| End Date: | April 2018 |
The goal of this study is to compare which treatment - BlephEx or MiBoFlo - will be a better
option for patients suffering from dry eye secondary to Meibomian Gland dysfunction.
option for patients suffering from dry eye secondary to Meibomian Gland dysfunction.
The investigators have previously studied the effect of the BlephEx instrument (debridement
of lid debris) in relieving signs and symptoms of blepharitis (Connor CG et al, ARVO 2014).
This previous study demonstrated positive results from the BlephEx treatment. Warming the
eyelids (e.g., using warm wash cloths) still remains a viable treatment option for this
disease. However, patients are often non-compliant with warm compress therapy due to the
requirement of performing it at least twice per day. The MiBoflo delivers uniform and
consistent amounts of heat to the eyelid. It is suggested that two treatments over 30 days is
adequate to relieve signs and symptoms of Meibomian gland dysfunction. This equipment is
currently used in optometric practices in this country.
There are no clinical studies comparing BlephEx and MiBoflo as treatment options for
blepharitis. Hence, the current study will provide new and useful information on which
treatment option may be better for treating blepharitis and Meibomian gland dysfunction. Part
of this study will also investigate if a combination of BlephEx and MiBoflo treatments is
more beneficial to the patient. The data generated will directly benefit clinical practice
and impact several millions of patients who suffer from this Blepharitis and / or Meibomian
gland dysfunction.
of lid debris) in relieving signs and symptoms of blepharitis (Connor CG et al, ARVO 2014).
This previous study demonstrated positive results from the BlephEx treatment. Warming the
eyelids (e.g., using warm wash cloths) still remains a viable treatment option for this
disease. However, patients are often non-compliant with warm compress therapy due to the
requirement of performing it at least twice per day. The MiBoflo delivers uniform and
consistent amounts of heat to the eyelid. It is suggested that two treatments over 30 days is
adequate to relieve signs and symptoms of Meibomian gland dysfunction. This equipment is
currently used in optometric practices in this country.
There are no clinical studies comparing BlephEx and MiBoflo as treatment options for
blepharitis. Hence, the current study will provide new and useful information on which
treatment option may be better for treating blepharitis and Meibomian gland dysfunction. Part
of this study will also investigate if a combination of BlephEx and MiBoflo treatments is
more beneficial to the patient. The data generated will directly benefit clinical practice
and impact several millions of patients who suffer from this Blepharitis and / or Meibomian
gland dysfunction.
Inclusion Criteria:
- Must have dry eye secondary to Meibomian gland dysfunction (posterior blepharitis)
Exclusion Criteria:
- Must not have active ocular surface infections. Must not be currently using steroids
or immunosuppression eye drops.
We found this trial at
1
site
Click here to add this to my saved trials
